

Efficacy and Safety of Tenugliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Li X et al. Front Pharmacol. 2018 May 4; 9:449.

- Ten trials with 2119 patients were analyzed. Tenugliptin led to greater decrease of fasting plasma glucose (FPG) level vs. placebo (-18.32%). Tenugliptin also significantly decreased the 2 h post-prandial plasma glucose (2 h PPG) by -46.94% vs. placebo.
- Tenugliptin produced absolute reductions in glycated hemoglobin (HbA1c) levels by 0.82% compared to placebo. The risks of hypoglycemia were not significantly different between tenugliptin and placebo.

Tenugliptin improved blood glucose levels and β -cells function with low risk of hypoglycemia in patients with T2DM. There was no significant difference between tenugliptin and placebo in overall adverse effects.